The novel WDR79–UHRF1–SIRT4 axis underscores the centrality of SIRT4 in inhibiting the aerobic glycolysis that fuels PDAC malignancy, positioning it as a pivotal antagonist of cancer metabolism. Here, SIRT4 is linked to cancer.